U.S. License Holder:
Date of License:
SKYRIZI (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of:
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy;
Active psoriatic arthritis in adults;
Moderately to severely active Crohn's disease in adults.
Inter Partes Review ProceedingsPTAB Portal
IPR Case No(s):
U.S. Patent No.
11,078,265 (Anti-IL-23 Antibodies)
Boehringer Ingelheim International GmbH
Sandoz, Inc.; Sandoz AG
§ 102 Challenge
§ 103 challenge
Challenges Include Written Description and Enablement. Awaiting Institution Decision